WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016095013) PHARMACEUTICAL COMPOSITION COMPRISING PLASMINOGEN AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/095013    International Application No.:    PCT/CA2015/000606
Publication Date: 23.06.2016 International Filing Date: 18.12.2015
IPC:
A61K 38/48 (2006.01), A61K 47/02 (2006.01), A61K 47/10 (2006.01), A61K 47/18 (2006.01), C12N 9/68 (2006.01)
Applicants: PROMETIC BIO THERAPEUTICS, INC. [US/US]; 1330 Piccard Drive, Suite 201 Rockville, MD 20850 (US)
Inventors: BLACKMAN, Davida; (US).
PLUM, Stacy; (US).
GARZON-RODRIGUEZ, William; (US).
YU, Betty; (US).
ROBITAILLE, Martin; (CA)
Agent: LECLAIRE, France; PROMETIC LIFE SCIENCES INC. 440, Armand-Frappier boulevard, Suite 300 Laval, Quebec H7V 4B4 (CA)
Priority Data:
62/094,556 19.12.2014 US
Title (EN) PHARMACEUTICAL COMPOSITION COMPRISING PLASMINOGEN AND USES THEREOF
(FR) COMPOSITION PHARMACEUTIQUE COMPRENANT DU PLASMINOGÈNE ET SES UTILISATIONS
Abstract: front page image
(EN)Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 μm which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.
(FR)L'invention concerne des compositions pharmaceutiques comprenant du plasminogène ou un variant biologiquement actif de ce dernier. Dans un mode de réalisation, la composition comprend un modificateur de tonicité, un agent de charge et un agent de stabilisation, et présente un pH compris entre environ 3,0 et environ 10,0. Dans un autre mode de réalisation, la composition contient un nombre de particules en suspension de taille égale ou supérieure à 10 μm ce qui est inférieur à 6 000 particules pour 100 mL, et de préférence inférieur à 2 000 particules pour 100 mL. Les utilisations de ces compositions comme médicament sont envisagées. Diverses utilisations thérapeutiques de ces compositions pharmaceutiques sont également décrites.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)